Down-regulation and aberrant cytoplasmic expression of GLTSCR2 in prostatic adenocarcinomas.
Down-regulation and aberrant cytoplasmic expression of GLTSCR2 in prostatic adenocarcinomas.
复制标题
DOI：
10.1016/j.canlet.2013.07.035
复制
发表时间：
2013-10
期刊：
影响因子：
9.7
通讯作者：
Jee-Youn Kim;Young-Eun Cho;G. Kim;Hyung‐Lae Lee;Sun Lee;Jae-hoon Park
中科院分区：
文献类型：
--
作者：
Jee-Youn Kim;Young-Eun Cho;G. Kim;Hyung‐Lae Lee;Sun Lee;Jae-hoon Park
GLTSCR 2是一种核/核仁蛋白，其易位至核质，在人类癌症中被抑制和突变。本研究的目的是研究GLTSCR 2的下调或胞质表达在前列腺癌的发生或发展中是否具有任何病理学意义。在这项研究中，我们发现GLTSCR 2在前列腺癌中受到抑制，其表达与Gleason评分显著相关。此外，我们还研究了GLTSCR 2下调和胞浆表达在前列腺癌发生发展中的发病机制。综上所述，我们的研究结果表明，GLTSCR 2功能作为一个肿瘤抑制剂在前列腺癌。
GLTSCR2 is a nuclear/nucleolar protein that translocates to the nucleoplasm, suppressed and mutated in human cancers. Our aim in this study was to investigate whether downregulation or cytoplasmic expression of GLTSCR2 has any pathological significance in prostatic cancer development or progression. In this study we show that GLTSCR2 is suppressed in prostatic cancers and its expression is significantly associated with Gleason’s scores. Furthermore, we investigated the pathogenetic mechanism of downregulation and cytoplasmic expression of GLTSCR2 in development or progression of prostatic cancers. Taken together, our results indicate that GLTSCR2 functions as a tumor suppressor in prostatic adenocarcinomas.